1. Home
  2. UONEK vs NEUP Comparison

UONEK vs NEUP Comparison

Compare UONEK & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urban One Inc. Class D

UONEK

Urban One Inc. Class D

N/A

Current Price

$5.06

Market Cap

26.8M

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.77

Market Cap

23.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UONEK
NEUP
Founded
1980
1996
Country
United States
United States
Employees
1272
8
Industry
Broadcasting
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
26.8M
23.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UONEK
NEUP
Price
$5.06
$4.77
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
16.8K
27.8K
Earning Date
05-14-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$3.65
52 Week High
$9.38
$21.31

Technical Indicators

Market Signals
Indicator
UONEK
NEUP
Relative Strength Index (RSI) 43.09 39.66
Support Level $4.75 $3.85
Resistance Level $6.12 $4.94
Average True Range (ATR) 0.64 0.21
MACD -0.02 -0.09
Stochastic Oscillator 17.14 25.00

Price Performance

Historical Comparison
UONEK
NEUP

About UONEK Urban One Inc. Class D

Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: